Heyuan Bio has released its 2026 interim report, with net profit attributable to the parent company at minus 101 million yuan. Total operating revenue was 122 million yuan, and net cash flow from operating activities was minus 82.92 million yuan. The latest asset-liability ratio is 34.56 percent, up 2.49 percentage points from the previous quarter and up 7.09 percentage points from the same period last year. The latest gross margin is minus 7.89 percent, the latest return on equity is minus 7.75 percent, and diluted earnings per share is minus 0.16 yuan. The company has 14,600 shareholders, and the top ten shareholders hold 229 million shares, accounting for 35.34 percent of total share capital.
OBiO Technology (Shanghai) Corp. Ltd. ACompany reports net loss of 101 million yuan in interim results.